Trade Report: Today: Flexion Therapeutics Inc. (FLXN) Insider Buys $29,904.70 in Stock

Today: Flexion Therapeutics Inc. (FLXN) Insider Buys $29,904.70 in Stock

Flexion Therapeutics Inc. (NASDAQ:FLXN) insider Michael D. Clayman acquired 1,666 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was acquired at an average cost of $17.95 per share, for a total transaction of $29,904.70. Following the completion of the purchase, the insider now directly owns 29,054 shares of the company’s stock, valued at approximately $521,519.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) opened at 18.33 on Monday. The stock’s market cap is $504.57 million. Flexion Therapeutics Inc. has a 12-month low of $7.56 and a 12-month high of $23.57. The company’s 50-day moving average is $19.23 and its 200-day moving average is $16.63.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Monday, November 7th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.02. On average, equities research analysts anticipate that Flexion Therapeutics Inc. will post ($2.76) earnings per share for the current year.

FLXN has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $40.00 price target on shares of Flexion Therapeutics in a research report on Wednesday, November 2nd. BCS dropped their price target on shares of Flexion Therapeutics from $0.65 to $0.02 in a research report on Tuesday, November 8th. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. Finally, Lake Street Capital reissued a “buy” rating and set a $38.00 price target on shares of Flexion Therapeutics in a research report on Tuesday, September 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Flexion Therapeutics currently has an average rating of “Buy” and an average target price of $28.28.

Several hedge funds have recently added to or reduced their stakes in FLXN. JPMorgan Chase & Co. increased its stake in Flexion Therapeutics by 4.1% in the first quarter. JPMorgan Chase & Co. now owns 118,000 shares of the specialty pharmaceutical company’s stock worth $1,086,000 after buying an additional 4,645 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Flexion Therapeutics during the first quarter worth $337,000. Bank of Montreal Can acquired a new stake in Flexion Therapeutics during the second quarter worth $204,000. Alps Advisors Inc. increased its stake in Flexion Therapeutics by 25.1% in the second quarter. Alps Advisors Inc. now owns 30,301 shares of the specialty pharmaceutical company’s stock worth $453,000 after buying an additional 6,078 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC increased its stake in Flexion Therapeutics by 27.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 4,307,870 shares of the specialty pharmaceutical company’s stock worth $64,467,000 after buying an additional 927,625 shares in the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

About Flexion Therapeutics

Related posts

Leave a Comment